YKL-40 in type 2 diabetic patients with different levels of albuminuria

European Journal of Clinical Investigation

Volumn 41, Issue 6, 2011, Pages 589-596

  Brix, Johanna M ^a   Höllerl, Florian ^b   Koppensteiner, Renate ^b   Schernthaner, Guntram ^a   Schernthaner, Gerit H ^b  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Type 2 diabetes and albuminuria; YKL 40

Indexed keywords

BIOLOGICAL MARKER; CREATININE; HEMOGLOBIN A1C; LIPID; UNCLASSIFIED DRUG; YKL 40;

ADULT; ALBUMINURIA; ARTICLE; BLOOD PRESSURE; BODY MASS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; VASCULAR DISEASE;

AGED; ALBUMINURIA; BIOLOGICAL MARKERS; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; GLYCOPROTEINS; HUMANS; LECTINS; MIDDLE AGED; REFERENCE VALUES; REGRESSION ANALYSIS; RISK FACTORS;

EID: 79955620770     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02446.x     Document Type: Article

References (25)

1. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-32.
2. Ninomiya T, Perkovic V, de GalanBE, Zoungas S, Pillai A, Jardine M et al. ADVANCE Collaborative Group Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009;20:1813-21.
3. Bakris GL. Albuminuria reduction and nephropathy progression. Curr Hypertens Rep 2008;10:388-9.
4. Jarrett RJ, Viberti GC, Argyropoulos A, Hill RD, Mahmud U, Murells TJ. Microalbuminuria predicts mortality in non-insulin dependent diabetics. Diabet Med 1984;1:17-9.
5. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damge: the Steno hypothesis. Diabetologia 1989;32:219-26.
6. Rathcke CN, Vestergaard H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res 2006;55:221-7.
7. Nøjgaard C, Høst NB, Christensen IJ, Poulsen SH, Egstrup K, Price PA et al. Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis 2008;19:257-63.
8. Wang Y, Ripa RS, Johansen JS, Gabrielsen A, Steinbruchel DA, Friis T et al. YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand Cardiovasc J 2008;42:295-302.
9. Nielsen AR, Erikstrup C, Johansen JS, Fischer CP, Plomgaard P, Krogh-Madsen R et al. Plasma YKL 40 a BMI independent marker of Type 2 diabetes. Diabetes 2008;57:3078-82.
10. Boot RG, van AchterbergTA, van AkenBE, Renkema GH, Jacobs MJ, Aerts JM et al. Strong induction of members of the chitinase family of proteins in arthersosclerosis: chitotriosidase and human cartilage gp-9 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol 1999;19:687-94.
11. Kucur M, Isman FK, Karadag B, Vural VA, Tavsanoglu S. Serum YKL-40 levels in patients with coronary artery disease. Coron Artery Dis 2007;18:391-6.
12. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Helsinki, Finland, 1964; amended in Tokyo, Japan, 1975; Venice, Italy 1983; Hong Kong 1989; Somerset West, South Africa, 1996; Edinburgh, Scotland, 2000; Washington, USA, 2002; Tokyo, Japan, 2004; published on Accessed on 20 November 2010.
13. ICH Harmonised Tripartite Guidline for Good Clinical Practice, published on Accessed on 22 November 2010.
14. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the MemberStates relating to the implementation of good clinical practice in theconduct of clinical trials on medicinal products for human use. Official Journal of the European Communities L/21/34 1·5·2001 published on Accessed on 22 November 2010.
15. ADA. Clinical Practice Recommondations. Diabet Care 2009;32(Suppl 1):S62-8.
16. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
17. Cockgroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
18. Levey AS, Greene T, Kusek JW, Beck GJ, Group MS. A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol 2000;11:A0828.
19. Matthwes DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
20. Groop PH, Thomas MC, Moran JL, Wadèn J, Thorn LM, Mäkinen VP et al. FinnDiane Study Group The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009;58:1651-8.
21. Rathcke CN, Johansen JS, Vestergaard H. YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflamm Res 2006;55:53-9.
22. Fach EM, Garulacan LA, Gao J, Xiao Q, Storm SM, Dubaquie YP et al. In vitro biomarker discovery for atherosclerosis by proteomics. Mol Cell Proteomics 2004;3:1200-10.
23. Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB et al. CLARICOR Trial Group High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J 2009;30:1066-72.
24. Rathcke CN, Persson F, Tarnow L, Rossing P, Vestergaard H. YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with Type 1 Diabetes and increases with levels of albuminuria. Diabetes Care 2009;32:323-8.
25. Hempen M, Kopp HP, Elhenicky M, Höbaus C, Brix JM, Koppensteiner R et al. YKL-40 is Elevated in Morbidly Obese Patients and Declines After Weight Loss. Obes Surg 2009;19:1557-63.